Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The relationship between mobility and polypharmacy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.11.19
Views: 89
Rating:

Prof Tanya Wildes - Washington University School of Medicine, St. Louis, USA

Prof Tanya Wildes speaks to ecancer at the SIOG 2019 meeting in Geneva about how polypharmacy affects mobility in older patients.

Firstly, Prof Wildes explored some of the current mobility tests and their conclusions in geriatric oncology assessments.

She then looked at how some of the conclusions (e.g. an increase in falls) also were the same risks associated of certain medications, and that this may impact mobility.

Prof Wildes concluded that there needs to be an accurate representation of the patient's medication so that mobility can be reviewed and understood in the context of their polypharmacy regimen.

More information on the Cancer and Ageing Research Group mentioned in the video can be found here.

This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.

Related videos

follow us

SIOG metastatic renal cell carcinoma


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation